Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
| Property | Pramlintide | Cagrilintide |
|---|---|---|
| Class | Amylin analogue | Amylin analogue (amylin & calcitonin receptor agonist) |
| Research category | diabetes and postprandial glucose | obesity and satiety |
| Evidence level | High | Moderate |
| Overall status | Approved (Rx, US) — limited availability | Not approved — phase 3 clinical research |
| FDA | Approved (Rx) | Not approved |
| EMA | Application withdrawn | Not approved |
| WADA | Check current list | Check current list |
| Mechanism studied | Pramlintide → Amylin receptors → Gastric emptying & glucagon ↓ → Postprandial glucose | Cagrilintide → AMY & calcitonin receptors → Hindbrain satiety signalling → Food-intake endpoints |
| Molecular weight | 3,949 g/mol | 4,409 g/mol |
| Sizes in stock | Not currently listed | 10mg |
Where the research overlaps
Both compounds are studied within Metabolic & GLP-1 research. Pramlintide is classed as amylin analogue, while Cagrilintide is amylin analogue (amylin & calcitonin receptor agonist). Evidence is rated high for Pramlintide and moderate for Cagrilintide.
For a full write-up, read Amylin Analogues: Pramlintide and Cagrilintide Reviewed.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.